Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Ahn, Byeong Cheol ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; IODINE;

CANCER DIAGNOSIS; DIFFERENTIATED THYROID CANCER; DOSIMETRY; HUMAN; MOLECULAR IMAGING; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; REDIFFERENTIATION THYROID CANCER; REVIEW; THYROID CANCER; PROCEDURES; THERANOSTIC NANOMEDICINE; THYROID NEOPLASMS;

HUMANS; IODINE ISOTOPES; MOLECULAR IMAGING; PRECISION MEDICINE; THERANOSTIC NANOMEDICINE; THYROID NEOPLASMS;

EID: 84973334406     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/1680464     Document Type: Review

References (39)

1. I. Gilham, Theranostics an Emerging Tool inDrug Discovery and Commercialisation, 2002, http://www. ddw-online. com/personalised-medicine/p148484-theranostics-an-emerging-tool-in-drugdiscovery-and-commercialisation-fall-02. html.
2. S. Jeelani, R. C. Jagat Reddy, T. Maheswaran, G. S. Asokan, A. Dany, and B. Anand, "Theranostics: A treasured tailor for tomorrow, " Journal of Pharmacy and Bioallied Sciences, vol. 6, supplement 1, pp. S6-S8, 2014.
3. S. M. Moghimi and Z. S. Farhangrazi, "Theranostics, " in Encyclopedia of Cancer, pp. 1-3, Springer, Berlin, Germany, 2015.
4. D. Y. Lee and K. C. P. Li, "Molecular theranostics: A primer for the imaging professional, " American Journal of Roentgenology, vol. 197, no. 2, pp. 318-324, 2011.
5. E. B. Silberstein, "Radioiodine: the classic theranostic agent, " Seminars in Nuclear Medicine, vol. 42, no. 3, pp. 164-170, 2012.
6. J.-R. Oh, B.-C. Ahn, S. Y. Jeong, S.-W. Lee, and J. Lee, "Radioiodine scan index: A simplified, quantitative treatment response parameter for metastatic thyroid carcinoma, " Nuclear Medicine and Molecular Imaging, vol. 49, no. 3, pp. 174-181, 2015.
7. D.-H. Kim, J.-H. Jung, S. H. Son et al., "Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonarymetastases of differentiated thyroid cancer, " Nuclear Medicine and Molecular Imaging, vol. 48, no. 1, pp. 55-62, 2014.
8. G. Dai, O. Levy, andN. Carrasco, "Cloning andcharacterization of the thyroid iodide transporter, " Nature, vol. 379, no. 6564, pp. 458-460, 1996.
9. B.-C. Ahn, "Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back, " Theranostics, vol. 2, no. 4, pp. 392-402, 2012.
10. D. S. Cooper, G. M. Doherty, B. R. Haugenet al., "RevisedAmerican thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, " Thyroid, vol. 19, no. 11, pp. 1167-1214, 2009.
11. B. R. M. Haugen, E. K. Alexander, K. C. Bible et al., "2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer, " Thyroid, vol. 26, no. 1, pp. 1-133, 2015.
12. E. L. Mazzaferri and S. M. Jhiang, "Differentiated thyroid cancer long-term impact of initial therapy, " Transactions of the American Clinical and Climatological Association, vol. 106, pp. 151-170, 1994.
13. E. L. Mazzaferri and S. M. Jhiang, "Long-term impact of initial surgical andmedical therapy on papillary and follicular thyroid cancer, "TheAmerican Journal ofMedicine, vol. 97, no. 5, pp. 418-428, 1994.
14. E. L. Mazzaferri and R. T. Kloos, "Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer, " Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1447-1463, 2001.
15. M. Luster, S. E. Clarke, M. Dietlein et al., "Guidelines for radioiodine therapy of differentiated thyroid cancer, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 10, pp. 1941-1959, 2008.
16. E. B. Silberstein, A. Alavi, H. R. Balon et al., "The SNMMI practice guideline for therapy of thyroid disease with 131I 3. 0, " Journal of Nuclear Medicine, vol. 53, no. 10, pp. 1633-1651, 2012.
17. H. Gharib, E. Papini, R. Paschke et al., "AmericanAssociationof Clinical Endocrinologists, AssociazioneMedici Endocrinologi, and EuropeanThyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules, " Endocrine Practice, vol. 16, supplement 1, pp. 1-43, 2010.
18. E. Tapscott, "The rectilinear scanner and an enduring legacy of education and research, " Journal ofNuclearMedicine, vol. 39, no. 5, pp. 16-33, 1998.
19. J. E. Kim, S. Kalimuthu, and B. Ahn, "In vivo cell tracking with bioluminescence imaging, " Nuclear Medicine and Molecular Imaging, vol. 49, no. 1, pp. 3-10, 2015.
20. C. M. Hong, B.-C. Ahn, S. Y. Jeong, S.-W. Lee, and J. Lee, "Distant metastatic lesions in patients with differentiated thyroid carcinoma: clinical implications of radioiodine and FDG uptake, " NuklearMedizin, vol. 52, no. 4, pp. 121-129, 2013.
21. J. W. Lee, H. S. Min, S. M. Lee, H. W. Kwon, and J. K. Chung, "Relations between pathological markers and radioiodine scan and 18F-FDG PET/CT findings in papillary thyroid cancer patients with recurrent cervical nodal metastases, " Nuclear Medicine andMolecular Imaging, vol. 49, no. 2, pp. 127-134, 2015.
22. B.-C. Ahn, "Applications of molecular imaging in drug discovery and development process, " Current Pharmaceutical Biotechnology, vol. 12, no. 4, pp. 459-468, 2011.
23. M. Salvatori and M. Luster, "Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 4, pp. 821-828, 2010.
24. S. H. Son, S. Lee, J. Jung et al., "Analysis of clinical factors for the determination of optimal serum level of thyrotropin after recombinant human thyroid-stimulating hormone administration, " Nuclear Medicine and Molecular Imaging, vol. 49, no. 4, pp. 268-275, 2015.
25. C. M. Hong, W. K. Lee, S. Y. Jeong, S.-W. Lee, B.-C. Ahn, and J. Lee, "Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation, " Nuclear Medicine Communications, vol. 35, no. 11, pp. 1119-1126, 2014.
26. C. Spitzweg, K. C. Bible, L. C. Hofbauer, and J. C. Morris, "Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets, " The Lancet Diabetes and Endocrinology, vol. 2, no. 10, pp. 830-842, 2014.
27. S. W. Oh, J. C. Paeng, and J. Chung, "New strategies for combined radioiodine therapy in refractory thyroid cancer, " Journal of Korean Thyroid Association, vol. 8, no. 1, pp. 26-35, 2015.
28. S. Micali, S. Bulotta, C. Puppin et al., "Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer, " BMC Cancer, vol. 14, no. 1, article 303, 2014.
29. S. M. Rothenberg, D. G. McFadden, E. L. Palmer, G. H. Daniels, and L. J. Wirth, "Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib, " Clinical Cancer Research, vol. 21, no. 5, pp. 1028-1035, 2015.
30. T. S. Plantinga, B. Heinhuis, D. Gerrits et al., "mTOR inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines, " Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, pp. E1368-E1375, 2014.
31. K.-P. Wong and B. H.-H. Lang, "New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review, " Journal of Thyroid Research, vol. 2012, Article ID 818204, 9 pages, 2012.
32. S. W. Oh, S.-H. Moon, D. J. Park et al., "Combined therapy with 131I and retinoic acid in Korean patients with radioiodinerefractory papillary thyroid cancer, " European Journal ofNuclear Medicine and Molecular Imaging, vol. 38, no. 10, pp. 1798-1805, 2011.
33. W. T. Shen andW.-Y. Chung, "Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferatoractivated receptor-agonists, " Thyroid, vol. 15, no. 6, pp. 594-599, 2005.
34. M. Xing, "Molecular pathogenesis and mechanisms of thyroid cancer, " Nature Reviews Cancer, vol. 13, no. 3, pp. 184-199, 2013.
35. M. Xing, B. R. Haugen, and M. Schlumberger, "Progress in molecular-based management of differentiated thyroid cancer, " The Lancet, vol. 381, no. 9871, pp. 1058-1069, 2013.
36. S. Beyer, A. Lakshmanan, Y.-Y. Liu et al., "KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells, " Endocrinology, vol. 152, no. 3, pp. 782-792, 2011.
37. T. D. Singh, S. Y. Jeong, S.-W. Lee et al., "Inverse agonist of estrogen-related receptor gamma enhances sodium iodide symporter function through mitogen-activated protein kinase signaling in anaplastic thyroid cancer cells, " Journal of Nuclear Medicine, vol. 56, no. 11, pp. 1690-1696, 2015.
38. S. J. Beyer, X. Zhang, R. E. Jimenez et al., "Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer, " BMC Research Notes, vol. 4, article 397, 2011.
39. A. L. Ho, R. K. Grewal, R. Leboeuf et al., "Selumetinibenhanced radioiodine uptake in advanced thyroid cancer, " The New England Journal of Medicine, vol. 368, no. 7, pp. 623-632, 2013.